

This is the peer reviewed version of the following article:

Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies / P., Avanzini; Vinceti, Marco; F., Ilariucci; L., Masini; M., Dinca; Vivoli, Gianfranco. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 80:(1995), pp. 505-511.

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

06/05/2026 23:34

SERUM SELENIUM CONCENTRATIONS IN PATIENTS WITH NEWLY DIAGNOSED LYMPHOID MALIGNANCIES

Paolo Avanzini*, Marco Vinceti°, Fiorella Ilariucci*, Luciano Masini*, Marco D'Incà*, Gianfranco Vivoli°

*Prima Divisione di Medicina Interna e Day-Hospital Ematologico, Arcispedale S. Maria Nuova, Reggio Emilia; °Sezione di Igiene, Dipartimento di Scienze Biomediche, Università di Modena, Modena, Italy

ABSTRACT

Background. Increased mortality from lymphoid malignancies following exposure to environmental selenium has recently been reported. Moreover, conflicting results have been found in investigations examining the relationship between serum concentrations of selenium and some clinical features of malignant lymphoproliferative diseases.

Methods. Serum concentrations of selenium were analyzed by atomic absorption spectrometry in fifty-nine patients with newly diagnosed chronic lymphoid malignancies and in forty control subjects

Results. Selenium concentrations were significantly lower in patients than in control subjects. However, when only patients with localized disease were compared to controls, no significant difference in serum selenium concentrations was observed. Clinical stage was inversely associated with selenium levels. High-grade non-Hodgkin's lymphoma was characterized by lower selenium levels than low-grade and intermediate-grade disease. Selenium levels were positively associated with albumin and hemoglobin, and inversely correlated with serum concentrations of β_2 -microglobulin and with erythrocyte sedimentation rate.

Conclusions. The findings of this study do not suggest that a high selenium intake represents a risk factor for malignant lymphoproliferative diseases, but limitations of the investigation hamper evaluation of the results. The possible utility of determining serum concentrations of selenium in the clinical evaluation of patients with lymphoid malignancies merits examination in larger studies.

Key words: selenium, serum, lymphoproliferative disorders, Hodgkin's disease; non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, neoplasms

Much scientific attention is currently focused on the possible role of selenium as an antineoplastic drug and the hypothetical involvement of this trace element in the etiology of human cancer. Great interest has been shown for some of the effects that pharmacological doses of selenium have on cell proliferation and viability, suggesting the possible use of selenium compounds as antineoplastic drugs.^{1,2} The serious toxicity of several selenium compounds, which seems to be strictly

related to the carcinostatic and cytotoxic activity of these compounds,³ however, hampers their consideration in clinical practice. The epidemiologic evidence linking selenium exposure to human cancer appears inconsistent, due to the conflicting results of recent ecologic investigations⁴⁻⁶ and case-control studies with both cross-sectional and prospective design.^{7,8} In fact, no association, an inverse one and a direct association between selenium exposure and cancer have been observed in these investigations. A

Correspondence: Dr. Paolo Avanzini, Day-Hospital Ematologico, Arcispedale S. Maria Nuova, Viale Umberto 10, 50, 42100, Reggio Emilia, Italy. Tel. international+39.522.296623 Fax. international+39.522.296604.

Acknowledgments: the present study was supported by the Foundation 'Manodori' of Reggio Emilia. The authors gratefully acknowledge the cooperation in the study of the following people: Andrea Di Ganci, Rita Filippi, Isello Fontana and Vincenzo Lusetti, general practitioners in the Local Health Unit of Reggio Emilia, for recruiting control subjects; Silvia Candela, Velmore Davoli, Milva Olmi, and Lorella Rinaldi of the Department of Occupational Health of Scandiano, Reggio Emilia for carrying out the selenium analyses.

Received April 13, 1995; accepted August 28, 1995.

tendency toward a positive association between selenium intake and the subsequent incidence of cancer has recently been reported in a large cohort-nested case-control study.⁹

Neoplasms of the lymphoid system represent one of the most frequently examined site-specific cancers in case-control studies with cross-sectional design for analyzing the possible relationship between serum concentrations of selenium and cancer,¹⁰⁻¹⁶ but the results of these studies have been conflicting. In two investigations a tendency toward higher selenium levels in patients with reticuloendothelial neoplasms¹⁰ and with Hodgkin's disease¹¹ was observed, whereas significantly low serum concentrations of selenium were reported in patients affected by chronic lymphocytic leukemia¹² and epidermotropic cutaneous T-cell lymphoma.¹⁶ Moreover, different results were obtained in these studies regarding the association between selenium status and the clinical stage of the neoplasms.

In a recent cohort study examining cancer mortality following accidental exposure to hexavalent selenium through drinking water, a higher mortality from non-Hodgkin's lymphoma and lymphoid malignancies was seen in females.¹⁷ Moreover, in a cohort of Baltic Sea fishermen, a higher mortality from multiple myeloma was observed in subjects whose diets provide a significant supplementation of selenium as well as other nutrients and pollutants.¹⁸

These observations led us to examine the serum levels of selenium in patients with newly diagnosed lymphoid malignancies and the possible association between the levels of this trace element and some clinical features of the disease.

Materials and Methods

A consecutive series of fifty-nine patients with suspected or newly diagnosed chronic lymphoid malignancies (Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia) referred to the Hematology Service of S. Maria Nuova Hospital in Reggio Emilia, northern Italy, were enrolled in the study. None of the patients had been previously treated.

Venous blood drawn in the morning after overnight fasting was immediately centrifuged for 10 min, and two serum aliquots of 1.5 mL from each patient were stored in plastic tubes at -12°C until analysis. In four cases, diagnosis of malignant lymphoproliferative disease was not confirmed, and these subjects were removed from the investigation. Eight of the patients included in the study (4 males and 4 females) were affected by Hodgkin's disease, 39 (27 males and 12 females) by non-Hodgkin's lymphoma, 7 (5 males and 2 females) by multiple myeloma and 5 (2 males and 3 females) by chronic lymphocytic leukemia.

The following hematologic parameters were also determined in several patients: erythrocyte sedimentation rate, hemoglobin, serum levels of albumin, β_2 -microglobulin, serum lactate dehydrogenase and copper.

Four general practitioners from the Local Health Unit in Reggio Emilia were asked to select a sample of the individuals on their rolls. Forty controls, 17 males and 23 females, agreed to participate in the study following an invitation from their family doctors and were referred to the Hematology Service. Blood samples from these individuals were obtained following the same procedures used in the patients.

Serum selenium was determined at the Laboratory of Industrial Toxicology of the Department of Occupational Health of Scandiano, Reggio Emilia, using atomic absorption spectrometry.¹⁹ A graphite furnace Perkin-Elmer 4100ZL atomic absorption spectrometer with background Zeeman correction was used for the analyses. Determinations were made in duplicate, and the analysts were blinded as to the case status of the specimens.

Spearman's rank correlation analysis was used to examine the relationship between serum selenium levels and age in the study population, and between selenium and the remaining hematologic variables in patients. Unpaired Student's t-test, analysis of variance and analysis of covariance were used for comparisons between means. A two-tailed p-value of less than 0.05 was considered significant in all procedures. The statistical analyses were carried out using the SPSS/PC+ software.

Results

Selenium concentrations were 92.3 ± 13.6 $\mu\text{g/L}$ in control subjects (100.2 ± 12 $\mu\text{g/L}$ in males and 86.5 ± 11.8 $\mu\text{g/L}$ in females) and 82.6 ± 15.5 $\mu\text{g/L}$ (83.6 ± 15.5 $\mu\text{g/L}$ in males and 80.6 ± 15.6 $\mu\text{g/L}$ in females) in patients with lymphoid malignancies ($p < 0.05$ vs. controls - Table 1). The difference in selenium concentrations between males and females was statistically significant in control subjects ($p = 0.001$) but not in patients ($p = 0.479$). In control subjects, age was not significantly correlated with serum selenium ($p = 0.759$), whereas a significant inverse correlation was observed in patients ($p = 0.002$). Serum concentrations of selenium in the different lymphoid malignancies are shown in Table 1. In comparison with controls, the serum levels of selenium were significantly lower in patients with non-Hodgkin's lymphoma ($p < 0.05$) and multiple myeloma ($p < 0.001$). Further adjustment for gender in the statistical analysis made the differences between controls and patients with non-Hodgkin's lymphoma significant at a p -level < 0.001 .

Serum selenium concentrations according to clinical stage in patients with non-Hodgkin's lymphoma are shown in Table 2. These concentrations were inversely associated with stage, and statistically significant differences were observed between patients with stage IV and stage I lymphoma. Results did not change significantly after adjustment for gender. Levels of selenium in stage I-II lymphomas were not significantly different from the values observed in

Table 1. Serum selenium levels (mean value \pm 1SD) in control subjects and in patients with lymphoid malignancies.

	<i>n</i>	<i>age (yr)</i>	<i>selenium ($\mu\text{g/L}$)</i>
control subjects	40	50.0 ± 14.5	92.3 ± 13.6
lymphoid malignancies	59	$58.4 \pm 15.7^*$	$82.6 \pm 15.5^*$
Hodgkin's disease	8	$35.9 \pm 8.9^*$	90.9 ± 8.2
non-Hodgkin's lymphoma	39	$60.8 \pm 14.5^*$	$83.2 \pm 14.9^*$
multiple myeloma	7	$65.3 \pm 10.7^*$	$69.1 \pm 18.8^\circ$
chronic lymphocytic leukemia	5	$65.8 \pm 4.9^*$	83.2 ± 15.8

* $p < 0.05$ vs. control subjects; $^\circ p < 0.001$ vs. control subjects

Table 2. Serum selenium levels in patients with non-Hodgkin's lymphoma according to clinical stage of the disease. Results are expressed as mean \pm 1SD (number of subjects).

	<i>selenium ($\mu\text{g/L}$)</i>
non-Hodgkin's lymphoma:	
stage 1	95.8 ± 15.4 (9)
stage 2	89.4 ± 7.4 (6)
stage 4	76.9 ± 12.7 (24)* $^\circ$

* $p < 0.001$ vs. control subjects; $^\circ p = 0.001$ vs. patients with stage 1 disease.

control subjects, whereas selenium concentrations in stage IV disease were significantly lower than in with controls ($p < 0.001$). A tendency toward lower levels of selenium in patients with more advanced disease was also observed in Hodgkins disease, multiple myeloma and chronic lymphocytic leukemia. In subjects with Hodgkins disease, selenium concentrations were 96.8 ± 6 , 90.3 ± 4.7 and 75.7 $\mu\text{g/L}$, respectively, in patients with stage I ($n = 3$), stage II ($n = 4$) and stage III ($n = 1$) disease.

In patients with non-Hodgkin's lymphoma, serum selenium was higher in intermediate-grade and lower in high-grade disease in comparison with low-grade disease (Table 3). Differences among the three groups were not statistically significant, but when clinical stage was included in the analysis as a confounder, a p -value of 0.003 was obtained. After adjustment for stage, selenium in patients with high-grade lymphoma was not significantly lower than in patients with low-grade disease ($p = 0.054$), whereas the difference between high-grade and intermediate-grade disease was statistically significant ($p < 0.001$). The difference in serum selenium concentrations between subjects with low-grade lymphoma and intermediate-grade disease was not statistically significant ($p = 0.119$). The presence of systemic symptoms in non-Hodgkin's lymphoma and Hodgkin's disease was not associated with significant differences in selenium concentrations with respect to patients without these symptoms. The level of selenium in the thirty-five patients with non-Hodgkins lymphoma reporting the presence of systemic symptoms was 83.7 ± 15.2 $\mu\text{g/L}$, while in the remaining four patients with lymphoma not reporting systemic symptoms selenium

Table 3. Serum selenium concentrations ($\mu\text{g/L}$) in patients with non-Hodgkin's lymphoma according to grade of the disease. Results are expressed as mean \pm SD (n)

	low grade	intermediate grade	high grade	p^*	p°
selenium levels	80.7 \pm 11.7(17)	87.7 \pm 16.6(17)	76.3 \pm 17.1(5)	0.515	0.003
adjusted [#] selenium levels	84.8	90.8	69.1		

* p -value at analysis of variance among the diagnostic groups; $^\circ p$ -value at analysis of variance among the diagnostic groups adjusting for clinical stage; [#]adjusted for clinical stage.

concentrations were 78.9 \pm 12.8 $\mu\text{g/L}$ ($p=0.55$).

In patients with lymphoid malignancies, selenium levels correlated positively with albumin and hemoglobin, whereas an inverse association with erythrocyte sedimentation rate and β 2-microglobulin was observed. Serum levels of copper and lactate dehydrogenase did not correlate with selenium concentrations. When analysis was restricted to patients with non-Hodgkin's lymphoma (Table 4), the results did not change significantly.

Discussion

In the present study, patients with newly diagnosed malignant lymphoproliferative diseases were found to have lower serum selenium levels than control subjects, but this difference was entirely due to the low selenium concentrations in patients with advanced disease. The findings of the study are in accordance with observations made in chronic lymphocytic leukemia¹³ and in epidermotropic cutaneous T-cell lymphoma,¹⁶ which show a tendency for serum selenium levels to decrease with progression of the disease, and that selenium levels in patients with early disease stages were not significantly different from the values observed in controls. In two other investigations which examined the relationship between the stage of lymphoid malignancies and serum selenium concentrations,^{11,12} no apparent association was observed, and serum selenium levels in the whole patient group were not significantly different from the values observed in controls. Most of the patients

Table 4. Correlation between serum selenium concentrations and hematologic parameters in patients with non-Hodgkin's lymphoma.*

	S°	p -value
albumin	0.413	0.011
β 2-microglobulin	-0.471	0.018
lactate-dehydrogenase	-0.270	0.123
copper	-0.030	0.869
erythrocyte sedimentation rate	-0.410	0.012
hemoglobin	0.376	0.018

*determinations were available in 37 patients for albumin, in 25 for β 2-microglobulin, in 34 for lactate dehydrogenase, in 32 for copper, in 37 for erythrocyte sedimentation rate and in 39 for hemoglobin; $^\circ$ Spearman's rank correlation coefficient.

examined in one of these investigations, however, had already received treatment for the disease.¹¹ The influence of therapy on serum selenium levels in lymphoid malignancies is controversial since it has been associated with either increased¹¹ to normal¹² serum selenium concentrations. It has been suggested that chemotherapy or radiotherapy might increase the release of selenium into the blood from the neoplastic tissue,^{10,11} which (as will be discussed later) has, at least in some types of tumors, a higher selenium content than the remaining tissues.²⁰⁻²³

The inverse association between progression of lymphoid malignancies and selenium status observed in the present study is consistent with previous observations in patients with cancer,²⁴⁻²⁷ although not all studies concur.^{28,29} The decreasing concentrations of selenium with disease progression might be due to disease-mediated dietary changes, which are more pronounced in patients with advanced disease. This hypothesis, however, was not tested in the present study or in previous investigations, to the best of our knowledge. In the patients with Hodgkin's disease and lymphoma examined in this study, however, no association was observed between selenium status and the presence of systemic symptoms, which might also have been linked to changes in dietary habits. A second hypothesis to explain the decreasing levels of selenium in untreated cancer patients with very advanced disease arises from the observation that selenium compounds tend to concentrate in neo-

plastic tissues in a variety of human and animal tumors.^{20-23,30-34} This phenomenon, which has been specifically examined in patients with Hodgkin's disease and non-Hodgkin's lymphoma and in animal models of lymphoma,^{30,32-34} represents the basis for the clinical use of labelled selenium compounds in tumor scintigraphy. Enhanced uptake of selenium by the neoplastic tissue might be responsible for depleting the trace element content of the blood and other tissues, thereby lowering serum selenium concentrations. It has also been noted in *in vivo* and *in vitro* animal studies that preferential uptake of labelled selenium compounds decreases following tumor irradiation,³⁵ and this fact might explain the lack of association between serum levels of selenium and the stage of the lymphoid malignancy when treated patients were examined.¹¹

The association observed in the present study between the grade of non-Hodgkin's lymphoma and selenium status suggests that high-grade lymphomas are linked to the lowest serum concentrations of the trace element. The number of patients with high-grade lymphoma, however, was very low and therefore these results must be evaluated with caution, especially since serum levels of selenium were higher in patients with intermediate-grade lymphoma than in those with low-grade disease. A tendency toward higher selenium concentrations in patients with well-differentiated lymphoid malignancies and non-Hodgkin's lymphoma has been reported.^{11,12} The absence in the present study of a relationship between serum selenium levels and the presence of systemic symptoms in patients with Hodgkins disease and lymphoma confirms previous reports.¹²

In agreement with observations in patients with cancer and other diseases,^{13,36,37} but unlike what was found in a group of patients with reticuloendothelial tumors,¹¹ a significant correlation between selenium levels and albumin was detected in the overall patient group as well as in the group with non-Hodgkin's lymphoma. A direct association between albumin and serum selenium levels might be explained by nutritional factors or by the fact that albumin represents a selenium-containing protein.³⁸ A variation in albumin and selenium independently indu-

ced by the progression of the lymphoid neoplasm might also be hypothesized. The association between hemoglobin and serum selenium observed in the present study in patients with non-Hodgkin's lymphoma was not supported in a previous investigation.¹¹ No other study, to our knowledge, has analyzed a possible association between selenium levels and erythrocyte sedimentation rate, serum levels of lactate dehydrogenase, copper and β 2-microglobulin in patients with non-Hodgkin's lymphoma. The inverse correlation of erythrocyte sedimentation rate and β 2-microglobulin with selenium found in this investigation deserves to be analyzed in larger studies.

Since in the present work a relationship was observed between serum selenium levels and hematologic parameters, stage and, in non-Hodgkin's lymphoma, grade, it seems appropriate to examine the possible utility of determining selenium status in the clinical evaluation of patients with lymphoid malignancies. Larger studies however are required to evaluate this possibility. Moreover, selenium status markers at clinical onset of a lymphoproliferative malignancy might represent a prognostic factor of the disease, as recently suggested in epidermotropic cutaneous T-cell lymphoma.¹⁶ Serum levels of selenium should therefore be considered for inclusion in future follow-up studies together with the prognostic factors identified so far or suggested in Hodgkins disease³⁹ and lymphoma.⁴⁰ The patients with non-Hodgkins lymphoma examined in the present study have been entered in a follow-up in order to analyze the possible relationship between serum levels of selenium at diagnosis of the disease and response to chemotherapy.

The findings of this study do not suggest that overexposure to selenium represents a risk factor for lymphoid malignancies since the levels of selenium in patients affected by stage I Hodgkin's disease and non-Hodgkin's lymphoma were only slightly elevated with respect to controls, whereas the number of patients affected by early-stage multiple myeloma and chronic lymphocytic leukemia was insufficient to yield meaningful data. Due to the cross-sectional design of the study, the above mentioned hypo-

thesis cannot be entirely ruled out however. In fact even in patients with localized disease, a disease-mediated decrease in serum selenium levels, a sensitive short-term marker of selenium intake and status,^{41,42} cannot be excluded, and this interferes with our ability to establish positive association between selenium intake and lymphoid malignancies. Moreover, the cancer-enhancing properties of selenium observed in some animal studies have been selectively associated with specific chemical forms of the trace element, such as hexavalent⁴³ or tetravalent⁴⁴ inorganic selenium, suggesting that analysis of exposure rather than evaluation of selenium status might be useful for detecting an association between selenium and human cancer. Nor do the results of the present study suggest that a low selenium status represents a risk factor for lymphoid malignancies, since the serum concentrations of selenium in patients with localized disease were no lower than those observed in controls. The results of this investigation do not however rule out a possible involvement of selenium in the etiology of lymphoid malignancies at intake levels considerably higher or lower than those typical of the Italian population examined in the study.

In conclusion, the results of the present study suggest that the serum concentration of selenium in newly diagnosed lymphoid malignancies is inversely associated with the clinical stage of the disease, but this relationship needs to be confirmed in larger studies. This investigation does not support the hypothesis of an involvement of high selenium intake in the etiology of malignant lymphoproliferative diseases, but the limitations of the study do not allow definitive conclusions to be drawn on this topic.

References

1. LeBoeuf RA, Laishes BA, Hoekstra WG. Effects of selenium on cell proliferation in rat liver and mammalian cells as indicated by cytokinetic and biochemical analysis. *Cancer Res* 1985; 45:5496-504.
2. Lu J, Kaeck M, Jiang C, Wilson AC, Thompson HJ. Selenium induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. *Biochem Pharmacol* 1994; 47:1531-5.
3. Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. *Free Radicals Biol Med* 1994; 17:45-64.
4. Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in U.S. Counties. *Arch Environ Health* 1991; 46:37-42.
5. Chen F, Cole P, Wen L, Mi Z, Trapido EJ. Estimates of trace element intakes in Chinese farmers. *J Nutr* 1994; 124:196-201.
6. Guo WD, Chow WH, Zheng W, Li JY, Blot WJ. Diet, serum markers and breast cancer mortality in China. *Jpn J Cancer Res* 1994; 85:572-7.
7. Stampfer MJ, Colditz GA, Willett WC. The epidemiology of selenium and cancer. *Cancer Surv* 1987; 6:623-33.
8. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. *Am J Epidemiol* 1992; 135:115-21.
9. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. *J Natl Cancer Inst* 1995; 87:497-505.
10. McConnel KP, Broghamer WL, Blotcky AJ, Hurt OJ. Selenium levels in human blood and tissues in health and in disease. *J Nutr* 1975; 1026-31.
11. Broghamer WL, McConnel KP, Grimaldi M, Blotcky AJ. Serum selenium and reticuloendothelial tumors. *Cancer* 1978; 41:1462-6.
12. Calautti P, Moschini G, Stievano BM, Tomio L, Calzavara F, Perona G. Serum selenium levels in malignant lymphoproliferative diseases. *Scand J Haematol* 1980; 24:63-6.
13. Beguin Y, Brasseur F, Weber G, et al. Observations of serum trace elements in chronic lymphocytic leukemia. *Cancer* 1987; 60:1842-6.
14. Mikac-Devic M, Ferenc D, Tiefenbach A. Serum selenium levels in untreated children with acute lymphoblastic leukemia I. *J Trace Elem Electrolytes Health Dis* 1990; 4:7-10.
15. Malvy DJM, Burtschy B, Arnaud J, et al. Serum β -carotene and antioxidant micronutrients in children with cancer. *Int J Epidemiol* 1993; 22:761-71.
16. Deffaut C, Celerier P, Boiteau HL, Litoux P, Dreno B. Serum selenium in melanoma and epidermotropic cutaneous T-cell lymphoma. *Acta Derm Venereol (Stockh)* 1994; 74:90-2.
17. Vinceti M, Rovesti S, Gabrielli C, et al. Cancer mortality in a residential cohort exposed to environmental selenium through drinking water. *J Clin Epidemiol* 1995; 48:1091-7.
18. Hagmar L, Linden K, Nilsson A, et al. Cancer incidence and mortality among Swedish Baltic Sea fishermen. *Scand J Work Environ Health* 1992; 18:217-24.
19. Morisi G, Patriarca M, Menotti A. Improved determination of selenium in serum by Zeeman atomic absorption spectrometry. *Clin Chem* 1988; 34:127-30.
20. Baur G, Wendel A. The activity of the peroxide-metabolizing system in human colon carcinoma. *J Cancer Res Clin Oncol* 1980; 97:267-73.
21. Rizk SL, Sky-Peck HS. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. *Cancer Res* 1984; 44:5390-4.
22. Di Ilio C, Del Boccio G, Casaccia R, et al. Selenium level and glutathione-dependent enzyme activities in normal and neoplastic human lung tissues. *Carcinogenesis* 1987; 8:281-4.
23. Itoh T, Kobayashi M, Tazawa T, Satoh H, Saito K. Selenium concentrations in gastric tissues of the patients with stomach cancer. *J Trace Elem Exp Med* 1989; 2:160-1.
24. Sundström H, Yrjänheikki E, Kauppila A. Serum selenium in patients with ovarian cancer during and after therapy. *Carcinogenesis* 1984; 5:731-4.
25. Overvad K, Grøn P, Langhoff O, Tarp U, Foldspang A, Thorling EB. Selenium in human mammary carcinogenesis: a case-referent study. *Eur J Cancer Prev* 1991; 1:27-30.
26. Lajtman Z, Nossio D, Romić Z, Trutin-Ostović K, Krpan D. Laryngeal cancer and blood selenium levels. *Eur Arch Otorhinolaryngol* 1994; 251:170-2.
27. Dworkin BM, Rosenthal WS, Mittelman A, Weiss L, Applebee-Brady L, Arlin Z. Selenium status and the poly-p-cancer

- sequence: a colonoscopically controlled study. *Am J Gastroenterol* 1988; 83:748-751
28. Goodwin WJ, Lane HW, Bradford K, et al. Selenium and glutathione peroxidase levels in patients with epidermoid carcinoma of the oral cavity and oropharynx. *Cancer* 1983; 51:110-5.
 29. Wasowicz W, Gromadzinska J, Sklodowska M, Wolkanin P, Zambrano Quispe OZ, Pluzanska A. Selenium concentrations and glutathione peroxidase activities in blood of breast cancer women. *Trace Elem Med* 1993; 10:168-72.
 30. Herrera NE, Gonzalez R, Schwartz RD, Diggs AM, Belsky J. ⁷⁵Se methionine as a diagnostic agent in malignant lymphoma. *J Nucl Med* 1965; 6:792-804.
 31. Cavalieri RR, Scott KG, Sairenji E. Selenite (⁷⁵Se) as a tumor-localizing agent in man. *J Nucl Med* 1966; 7:197-208.
 32. Herrera NE, Gonzalez RD, Kranwinkel RN. Further investigations on the role of selenomethionine Se 75 uptake in the diagnosis of lymphoma. *Lahey Clin Found Bull* 1968; 17:43-9.
 33. Spencer RP, Montana G, Scanlon GT, Evans OR. Uptake of selenomethionine by mouse and in human lymphomas, with observations on selenite and selenate. *J Nucl Med* 1967; 8:197-208.
 34. Hara T, Tilbury S, Freed BR, Wooddard HQ, Laughlin JS. Production of ⁷⁵Se in cyclotron and its uptake in tumors of mice. *Int J Appl Radiat Isot* 1973; 24:377-84.
 35. Nordman E, Jaszgagi-Nagy E, Rekonen A. Changes in tumour cell selenite (⁷⁵Se) affinity due to irradiation. *Ann Clin Res* 1976; 8:43-7.
 36. Robinson MF, Godfrey PJ, Thomson CD, Rea HM, van Rij AM. Blood selenium and glutathione peroxidase activity in normal subjects and in surgical patients with and without cancer in New Zealand. *Am J Clin Nutr* 1979; 32:1477-85.
 37. Åkesson B. Plasma selenium in patients with abnormal plasma protein patterns. *Trace Elem Med* 1987; 4:77-9.
 38. Deagen JT, Beilstein MA, Whanger PD. Chemical forms of selenium containing proteins from human plasma. *J Inorg Biochem* 1991; 41:261-8.
 39. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Bertoloni D, Ascari E. Estimate of expected survival at diagnosis in Hodgkins disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the international database on Hodgkins disease (IDHD). *Haematologica* 1994; 79:241-55.
 40. Federico M, Gobbi PG, Barbieri F, Silingardi V. Relationship between prognostic factors and therapy in high-grade non-Hodgkin's lymphomas over two decades. *Haematologica* 1989; 74:511-9.
 41. Brätter P, Negretti de Brätter VE, Gawlik D, Oliver WL, Alvarez N, Jaffi W. Selenium in human monitors related to the regional dietary intake levels in Venezuela. *J Trace Elem Electrolytes Health Dis* 1993; 7:111-2.
 42. Levander OA. The need for measures of selenium status. *J Am Coll Toxicol* 1986; 5:37-44.
 43. Schroeder HA, Mitchener M. Selenium and tellurium in rats: effect on growth, survival and tumors. *J Nutr* 1971; 101:1531-40.
 44. Ankerst J, Sjögren HO. Effect of selenium on the induction of breast fibroadenomas by adenovirus type 9 and 1,2-dimethylhydrazine-induced bowel carcinogenesis in rats. *Int J Cancer* 1982; 29:707-10.